SCHEMBL30869764

SCHEMBL30869764

c1cc2c(cc1-c1ccc3[nH]ncc3c1)Oc1cc(-c3ccc4[nH]ncc4c3)cnc1N2CCCCN1C[C@@H]2C[C@H]1CO2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 4/20 0.42
KCNH2 Q12809 1/20 0.41
GSK3B P49841 6/20 0.37
DYRK1A Q13627 6/20 0.37
WNT1 P04628 4/20 0.37
USP30 Q70CQ3 1/20 0.35
KRAS P01116 1/20 0.33
BRAF P15056 1/20 0.33
ROCK2 O75116 3/20 0.33
ROCK1 Q13464 3/20 0.33
PTPN11 Q06124 1/20 0.33
DYRK3 O43781 2/20 0.32
CLK2 P49760 2/20 0.32
CDK5 Q00535 2/20 0.32
CLK4 Q9HAZ1 2/20 0.32
CDC7 O00311 1/20 0.32
DAPK3 O43293 1/20 0.32
CDK1 P06493 1/20 0.32
RPS6KB1 P23443 1/20 0.32
CDK2 P24941 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30869736 1.00 CHRNA7 (0.42) CHRNA7KCNH2GSK3BDYRK1AWNT1
SCHEMBL30869632 0.99 CHRNA7 (0.41) CHRNA7KCNH2GSK3BDYRK1AWNT1
SCHEMBL30869435 0.99 CHRNA7 (0.41) CHRNA7KCNH2GSK3BDYRK1AWNT1
SCHEMBL30869440 0.96 CHRNA7 (0.43) CHRNA7KCNH2GSK3BDYRK1AWNT1
SCHEMBL30869791 0.96 CHRNA7 (0.43) CHRNA7KCNH2GSK3BDYRK1AWNT1
SCHEMBL30869787 0.95 CHRNA7 (0.42) CHRNA7KCNH2GSK3BDYRK1AWNT1
SCHEMBL30869394 0.95 CHRNA7 (0.42) CHRNA7KCNH2GSK3BDYRK1AWNT1
SCHEMBL30869522 0.92 CHRNA7 (0.42) CHRNA7KCNH2GSK3BDYRK1AWNT1
SCHEMBL30869702 0.92 CHRNA7 (0.42) CHRNA7KCNH2GSK3BDYRK1AWNT1
SCHEMBL30869718 0.92 CHRNA7 (0.41) CHRNA7KCNH2GSK3BDYRK1AWNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260070880-A1 DYNAMIN ACTIVATORS WALDEN BIOSCIENCES, INC. (US) 2026-03-12 US disclosed
EP-4583868-A2 DYNAMIN ACTIVATORS Walden Biosciences, Inc. (US) 2025-07-16 EP disclosed
WO-2024054661-A2 DYNAMIN ACTIVATORS WALDEN BIOSCIENCES (US) 2024-03-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260070880-A1 DYNAMIN ACTIVATORS DNM1, DNM1L, DNM2 CHRNA7 1850/4885KCNH2 851/4885GSK3B 3383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.